Ruizheng Gene
Suzhou
About Ruizheng Gene
AccurEdit develops and commercializes safe and targeted in vivo gene editing and delivery technologies to treat severe hereditary and acquired diseases globally. The company has built a leading end-to-end platform specializing in RNA synthesis, gene editing, and delivery for in vivo gene editing therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $75.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2025)
- Website: accuredit.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Genetics, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ruizheng-gene-20005 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.